Search Results

You are looking at 51 - 60 of 107 items for :

  • "aromatase inhibitor" x
  • User-accessible content x
Clear All
Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis

to aromatase inhibitors (AIs). Analysis To summarize demographic, chart review, pharmacy, and interview data, we used descriptive statistics, SAS 9.3, and 2-tailed tests. Using chi-square and Fisher exact tests, we compared PCP versus cancer

Full access

Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz

improving progression-free survival in patients with hormone receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Common side effects of everolimus include stomatitis, rash, diarrhea, fatigue, and upper

Full access

Therese B. Bevers

aromatase inhibitors (AIs) exemestane and anastrozole have shown even greater breast cancer risk reduction for women at increased risk of developing the disease. 5 , 6 However, the trials were small and these agents are not currently FDA-approved for this

Full access

Scott Ramsey and Veena Shankaran

: 36 – 46 . 23 Sedjo RL Devine S . Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer . Breast Cancer Res Treat 2011 ; 125 : 191 – 200 . 24 Kelley RK Venook AP

Full access

Julia C. Shih and Anthony J. Olszanski

. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1

Full access

Azeez Farooki

with various cancer therapies, including aromatase inhibitor (AI) therapy in postmenopausal women and AI therapy and gonadotropin-releasing hormone (GnRH) agonists in pre-menopausal women with breast cancer, bone marrow transplantation in patients with

Full access

Presenter: William J. Gradishar

cells become resistant to antiestrogen therapy. With knowledge of these pathways, these targets became druggable, he said. Figure 2. Examples of hormonal therapies for ER+ breast cancer: evidence of recent acceleration. Abbreviations: AI, aromatase

Full access

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

6 months after treatment. Median and mean time taking opioids was 0.7 and 1.9 weeks, respectively. New opioid users were more likely to receive multimodality treatment and aromatase inhibitors, and persistent opioid users were more likely to receive

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

2006 ; 11 : 704 – 717 . 42 Miller WR Bartlett J Brodie AM . Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008 ; 13 : 829 – 837 . 43 Normanno

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

significantly improve PFS compared with hormone therapy alone in patients with advanced HR+/HER2– breast cancer, 6 , 7 leading to FDA approval of palbociclib in combination with an aromatase inhibitor (AI; as first-line therapy) in February 2015, and with